Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML0567

Sigma-Aldrich

BRD4770

≥98% (HPLC)

Synonym(s):

2-(Benzoylamino)-1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylic acid methyl ester

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
₩178,539
25 MG
₩715,880

₩178,539

Please contact Customer Service for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
₩178,539
25 MG
₩715,880

About This Item

Empirical Formula (Hill Notation):
C25H23N3O3
CAS Number:
1374601-40-7
Molecular Weight:
413.47
MDL number:
MFCD23143627
UNSPSC Code:
12352200
PubChem Substance ID:
329825558
NACRES:
NA.77

₩178,539

Please contact Customer Service for Availability
Request a Bulk Order

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

O=C(C1=CC=CC=C1)NC2=NC3=C(N2CCCC4=CC=CC=C4)C=CC(C(OC)=O)=C3

InChI

1S/C25H23N3O3/c1-31-24(30)20-14-15-22-21(17-20)26-25(27-23(29)19-12-6-3-7-13-19)28(22)16-8-11-18-9-4-2-5-10-18/h2-7,9-10,12-15,17H,8,11,16H2,1H3,(H,26,27,29)

InChI key

UCGWYCMPZXDHNR-UHFFFAOYSA-N

Related Categories

Biochem/physiol Actions

BRD4770 is a selective inhibitor of the histone methyltransferase G9a.
BRD4770 is a selective inhibitor of the histone methyltransferase G9a. BRD4770 blocks lysine residue 9 methylation of histone H3 without inducing apoptosis. In PANC-1 cells, BRD4770 activates the ataxia telangiectasia mutated (ATM) pathway, induces senescence and inhibits anchorage-dependent and -independent growth.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000033009
0000033010
122M4606V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Guillermo Urrutia et al.
Molecular cancer research : MCR, 18(3), 448-462 (2019-12-12)
Because of its dismal outcome, pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge making the testing of new pharmacologic tools a goal of paramount importance. Here, we developed a rational approach for inhibiting PDAC growth based on leveraging cell-cycle arrest

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service